It took my savings and 14 years – but I'm about to cure arthritis
Simon Westbrook developed LEVI-04, a promising osteoarthritis drug, after being laid off. Phase-two trials showed significant pain reduction. It may be available on the NHS in three to four years.
Read original articleSimon Westbrook, after being laid off from Pfizer in 2011, dedicated 14 years and his savings to develop a new drug for osteoarthritis, known as LEVI-04. This drug, which can be administered via a monthly EpiPen-style injection, aims to restore protective processes in diseased joints and alleviate pain by blocking pain signal transmission. The drug has shown promising results in phase-two trials involving 510 patients, with many reporting significant pain reduction and improved mobility. Westbrook's journey included financial struggles, including living in a camper van to save costs while seeking investors. His efforts culminated in a successful trial that could lead to the drug being available on the NHS within three to four years. The drug is expected to benefit the estimated 600 million people suffering from osteoarthritis globally and may also be applicable for treating rheumatoid arthritis and chemotherapy-induced pain in the future. Westbrook's story highlights the challenges and determination involved in drug development, as well as the potential for significant improvements in quality of life for patients.
- Simon Westbrook developed LEVI-04 after being laid off from Pfizer.
- The drug has shown significant effectiveness in reducing pain for osteoarthritis patients.
- Phase-two trials involved 510 patients, with many experiencing improved mobility.
- LEVI-04 could be available on the NHS within three to four years.
- The drug may also be applicable for other types of pain management in the future.
Related
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
New biomaterial regrows damaged cartilage in joints
Northwestern University researchers created a bioactive material that regenerates knee cartilage, tested in sheep, potentially preventing knee replacements and treating osteoarthritis by promoting durable hyaline cartilage growth.
Cell-Free Bioactive Scaffold Supports Cartilage Regeneration-Large Animal Joints
Northwestern University researchers created a bioactive scaffold for cartilage regeneration in sheep, promoting new cartilage growth and potentially preventing knee replacements, with applications for human medicine indicated by successful large-animal trials.
New biomaterial regrows damaged cartilage in joints
Northwestern University researchers created a bioactive material that regenerates knee cartilage, showing significant repair in sheep models. This innovation may replace knee surgeries and treat osteoarthritis effectively.
- Many commenters question the drug's efficacy, suggesting it may primarily serve as a painkiller rather than a cure for osteoarthritis.
- Concerns are raised about the legal implications of Westbrook's use of a molecule discovered while working at Pfizer.
- Several users share personal experiences with arthritis and dietary interventions, indicating a broader interest in alternative treatments.
- There is a general skepticism about the hype surrounding new drug developments, with references to past failures in clinical trials.
- Some commenters express hope for the drug's potential while acknowledging the challenges ahead in the approval process.
This is the only publication I found in a quick search:
https://pubmed.ncbi.nlm.nih.gov/37976118/
>> Abstract
Objectives: Nerve growth factor β (β-NGF) is a protein which is important to the development of neurons particularly those involved in the transmission of pain and is central to the experience of pain in osteoarthritis (OA). Direct NGF antagonism has been shown to reduce OA pain but is associated with rapidly progressive OA. The aim of the study is to investigate the ability of soluble neurotrophin receptors in the NGF pathway to modulate pain in OA.
Methods: Synovial fluid (SF) was obtained from the knee joints of 43 subjects who underwent total knee arthroplasty. Visual analogue scale (VAS) pain scores were obtained prior to surgery. Customised-automated-ELISAs and commercial-ELISAs and LEGENDplex™ were used to measure soluble low-affinity nerve growth factor (LNGFR), soluble tropomyosin receptor kinase (TrkA), proNGF, β-NGF, other neurotrophins (NT) and cytokines including inflammatory marker TNF-α.
Results: The VAS score positively correlated with β-NGF (r=0.34) and there was positive association trend with neurotrophin-3 (NT-3), BDNF and negative association trend with ProNGF. sLNGFR positively correlated with VAS (r=0.33). The β-NGF/soluble TrkA ratio showed a strong positive correlation with VAS (r=0.80). In contrast, there was no correlation between pain and the β-NGF/sLNGFR ratio (r=-0.08). TNF-α positively correlated with β-NGF (r=0.83), NT-3 (r=0.66), and brain-derived neurotrophic factor (BDNF) (r=0.50) and negatively with ProNGF (r= -0.74) and positively correlated with both soluble TrkA (r=0.62), sLNGFR (r=0.26).
Conclusions: This study suggests that endogenous or cleaved sLNGFR, but not soluble TrkA may participate in OA pain modulation thus supporting further research into soluble LNGFR as a therapeutic target in OA.
So, it restores lost tissue by numbing nerves? This makes no sense.
Wonder if it's just poor reporting or if there is something to this?
On leaving the company, he acquired the intellectual property [IP] rights from his former employer
A lot of people don't do this when they leave or are terminated. It doesn't usually succeed, but it's always worth at least making the attempt. (In this case, Pfizer gave him the IP rights to the molecule he discovered in exchange for a portion of his company.)
Now I'm at a point I would only be fine with saying this if I didn't have any issues after a prolonged interval.
(Not sure if I have arthritis but really sore hips and lower back.)
I had read that fatty fishes were a good source to reduce pain but in your experience, is there any other food/lifestyle changes that can help alleviate it before resorting to medication?
Thinks can go wrong in Phase III.
Relyvrio (HIV vaccine) did well in P2 but flopped on P3.
Cancer drug xevinapant failed in P3 after Merck executives were reassuring analysts that the failure of a phase 3 trial of xevinapant was “unlikely.”
My rheumatologist wanted to put me on methotrexate but I declined out of fear if the side effects. He never mentioned anything about diet, but clearly a dietary intervention worked for me.
This looks more promising: https://www.youtube.com/watch?v=pQ1CLtc8oIk
Many times, I met people who genuinely believed they were super close and about to achieve a "huge" breakthrough.
In each case, the scientists themselves, in their minds, were absolutely convinced they were on the brink of unfathomable achievements: curing Alzheimers, or some cancers etc.
Particularly true for the scientists in biomedical startups - they were like Mulder from X-Files; they all wanted (and were desperately eager) to believe. Like Elizabeth Holmes of Theranos, I think she completely believed her own exaggerations and BS - at some point, fact and fiction merge.
Thus I've become extraordinarily skeptical of articles like these.
More like Pfizer invested in an employee's startup.
> The drug is based on a molecule he discovered while working at Pfizer
tells me that he'd better have good lawyers on speed-dial.
> It works by blocking a compound that supports the nerve cells involved in transmitting pain signals to the brain.
Unfortunately it doesn't fix the underlying issue.
I can see Pfizer lawyers salivating uncontrollably after reading that phrase. Extremely unwise of him to mention this.
Is Pharma different than Engineering in terms of IP?
If my former employer has evidence that what I am working on in a new gig was discovered while on company time using company resources couldn't they sue?
Related
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
New biomaterial regrows damaged cartilage in joints
Northwestern University researchers created a bioactive material that regenerates knee cartilage, tested in sheep, potentially preventing knee replacements and treating osteoarthritis by promoting durable hyaline cartilage growth.
Cell-Free Bioactive Scaffold Supports Cartilage Regeneration-Large Animal Joints
Northwestern University researchers created a bioactive scaffold for cartilage regeneration in sheep, promoting new cartilage growth and potentially preventing knee replacements, with applications for human medicine indicated by successful large-animal trials.
New biomaterial regrows damaged cartilage in joints
Northwestern University researchers created a bioactive material that regenerates knee cartilage, showing significant repair in sheep models. This innovation may replace knee surgeries and treat osteoarthritis effectively.